Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors

Exclusion Criteria

• •1. Patients previously diagnosed with any ILD or interstitial lung abnormality (ILA)
• •2. Patients who have had a chest computerized tomography (CT) in the past 2 years
• •3. Pregnancy at time of HRCT (to be checked in women of child-bearing potential before scan)
• •4. Unwilling or unable to obtain HRCT
• •5. Patients previously received drugs or treatments that are known to induce ILD (e.g., radiation therapy to chest region, bleomycin). Note: All disease-modifying antirheumatic drugs (DMARDs) including methotrexate and biologics are allowed.
• •6. Patients who have had a lung transplant
• •7. Patients suspected of having developed ILD due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection / coronavirus disease 19 (COVID-19) (based on Investigators' judgement)
• •8. Patients diagnosed with another autoimmune disorders overlapping with RA-associated with the development of ILD (systemic sclerosis, myositis, dermatomyositis, mixed connective tissue disease, systemic lupus erythematosus, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis or primary Sjogren's syndrome)
• •9. Patients currently enrolled in an investigational new drug trial